7Baggers

Beyond Air, Inc
(NASDAQ:XAIR) 

XAIR stock logo

Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the...

Founded: 2011
Full Time Employees: 23
CEO: Steven A. Lisi  
Sector: Healthcare
Industry: Medical Devices
Medical Devices
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
  • Early-Stage MedTech Profile with Commercialization Focus: Beyond Air, Inc. operates as an early-stage medical device company focused on bringing its nitric oxide–based respiratory therapies toward broader clinical and commercial adoption.
  • Primary Value Driver: Adoption and Utilization Growth: Near-term performance is typically driven by hospital/clinic uptake, expanding site count, and increasing utilization per site as clinicians gain familiarity and protocols mature.
  • Financials Often Characterized by Operating Losses and Cash Burn: As a developing commercial-stage company, results commonly include ongoing net losses and negative operating cash flow, with investors tracking the pace of burn, gross margin progression, and operating expense discipline.
  • Catalysts Centered on Regulatory, Clinical, and Commercial Milestones: Key upside or downside inflections frequently come from regulatory clearances/approvals, clinical data readouts, reimbursement coverage progress, and distribution/partnership expansion.
  • Balance Sheet and Funding Needs Are a Central Investor Watch Item: Liquidity runway, access to capital (equity or debt), and any potential dilution are often central considerations given the company’s investment phase and the need to fund commercial scale-up.
Bull Thesis:
  • Differentiated Technology Driving Market Adoption: Beyond Air's LungFit PH system offers a unique on-demand nitric oxide generation, eliminating bulky cylinders and potentially reducing operational costs for hospitals. Early commercial traction and positive feedback could accelerate adoption in the neonatal hypoxic respiratory failure market, displacing traditional methods.
  • Significant Pipeline for Market Expansion: Beyond Air is actively pursuing additional indications for its nitric oxide delivery platform, including bronchiolitis, non-tuberculous mycobacteria (NTM), and potentially other respiratory conditions. Successful clinical trials and regulatory approvals in these areas would dramatically expand the total addressable market beyond its initial neonatal indication.
  • Operational Efficiencies and Cost Savings for Hospitals: The LungFit PH system's ability to generate nitric oxide from ambient air can lead to substantial operational efficiencies for hospitals, including reduced logistics, storage requirements, and waste associated with traditional gas cylinders. These long-term cost savings and simplified operations could be a strong driver for widespread adoption.
Bear Thesis:
  • Persistent Cash Burn and Future Dilution Risk: As an early-stage commercial company, Beyond Air continues to incur significant operating expenses related to R&D, sales, and marketing. The company's negative free cash flow trajectory suggests a continued need for external funding, potentially leading to further equity dilution for existing shareholders to sustain operations.
  • Slower-than-Expected Commercial Ramp-Up: Despite the innovative technology, hospital adoption of new medical devices can be a lengthy process due to budget cycles, clinical evaluations, and established relationships with incumbent providers. A slower-than-anticipated commercial ramp-up for LungFit PH could impact revenue growth and profitability timelines, falling short of investor expectations.
  • High Reliance on Future Pipeline Success: A significant portion of Beyond Air's long-term valuation may be predicated on the successful development and commercialization of its nitric oxide platform for indications beyond neonatal hypoxic respiratory failure. Any delays, failures, or unfavorable trial results in its pipeline programs (e.g., bronchiolitis, NTM) could severely impact future growth prospects and valuation.
  • Competitive Landscape and Market Penetration Challenges: Beyond Air faces competition from established players in the nitric oxide delivery market, such as Mallinckrodt (INOmax), which have strong market presence and existing hospital relationships. Overcoming these entrenched competitors and achieving significant market penetration could prove challenging and costly, requiring substantial sales and marketing investment.
Main Competitors:
  • Linde PLC ($LIN) (INOmax (nitric oxide for inhalation) and INOmax DSIR delivery system), Linde PLC is the dominant player in the inhaled nitric oxide market, particularly for Persistent Pulmonary Hypertension of the Newborn (PPHN), with its established INOmax product and tank-based delivery system. Beyond Air's LungFit NO system aims to compete by offering a tankless, on-demand nitric oxide generation and delivery solution, potentially disrupting Linde's market share.
  • Insmed Incorporated ($INSM) (Arikayce (amikacin liposome inhalation suspension)), Insmed has an approved inhaled antibiotic, Arikayce, for refractory Mycobacterium avium complex (MAC) lung disease, a form of non-tuberculous mycobacteria (NTM) lung disease. This directly competes with Beyond Air's inhaled nitric oxide program, which is in clinical trials for NTM lung infections, aiming to offer an alternative or complementary treatment.
  • Bellerophon Therapeutics, Inc. ($BLPH) (INOpulse (pulsatile inhaled nitric oxide delivery system)), Bellerophon is developing a pulsatile inhaled nitric oxide delivery system (INOpulse) for various forms of pulmonary hypertension (e.g., PH-ILD, PH-COPD). While their primary indications differ from Beyond Air's PPHN focus, they represent another company innovating in the inhaled nitric oxide space, potentially competing for market share and technological advancements in the broader iNO therapeutic area.
Moat:
Beyond Air's primary competitive advantage (moat) lies in its proprietary LungFit NO system, which offers a tankless, on-demand generation and delivery of nitric oxide. This innovative technology, protected by intellectual property, aims to provide significant logistical, safety, and cost benefits over traditional tank-based systems like Linde's INOmax, potentially disrupting the existing inhaled nitric oxide market. However, Beyond Air faces substantial competition from established market leaders such as Linde PLC, which dominates the PPHN market with INOmax, and Insmed Incorporated, which has an approved inhaled therapy (Arikayce) for NTM lung disease, a key pipeline indication for Beyond Air. Additionally, other companies like Bellerophon Therapeutics are also innovating in the broader inhaled nitric oxide space. Beyond Air's success hinges on demonstrating superior clinical outcomes, achieving regulatory approvals, and effectively penetrating markets dominated by entrenched competitors with existing infrastructure and physician familiarity.
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-12-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 
                                          
      revenues
    		1,907,000 2,194,000 1,818,000 1,760,000 1,152,000 1,072,000 798,000 683,000    59,000                           
      cost of revenues
    		1,813,000 1,894,000 2,116,000 -1,604,000 -9,552,000 1,287,000 1,882,000 -1,016,000    303,000                           
      gross profit
    		94,000 300,000  156,000         -61,750 -68,000 -179,000                        
      yoy
    		                                      
      qoq
    		-68.67%            -9.19% -62.01%                         
      gross margin %
    		Infinity% Infinity% NaN% Infinity% NaN% NaN% NaN% NaN% 0% 0% 0% NaN% -Infinity% -Infinity% -Infinity% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN%  NaN% NaN% NaN% NaN% NaN% 
      operating expenses:
    		                                      
      research and development
    		2,276,000 2,429,000 -2,450,000 -3,086,000 -3,258,000 -3,005,000 -4,585,000 -6,009,000 -5,699,000 -6,838,000 -7,130,000 -4,695,000 -29,489,000 5,000,000 4,452,000 3,226,000 -19,893,000 2,543,000 2,807,000 2,741,041 -23,391,541 3,294,102 3,147,276 4,331,814 -2,894,795 -2,580,622 -2,849,990 2,323,513 -6,228,825 586,696         
      selling, general and administrative
    		4,988,000 4,467,000 -4,913,000 -4,687,000 -3,884,000 -7,732,000 -7,163,000 -7,239,000    -10,936,000                           
      total operating expenses
    		7,264,000 6,896,000 -7,363,000 -7,773,000 -7,142,000 -10,737,000 -11,748,000 -13,247,000                               
      income from operations
    		-7,170,000 -6,596,000 -7,661,000 -7,617,000 -7,174,000 -10,952,000 -12,833,000 -13,580,000                           -8,684  -2,540 -2,897 
      yoy
    		-0.06% -39.77% -40.30% -43.91%                                   
      qoq
    		8.70% -13.90% 0.58% 6.18% -34.50% -14.66% -5.50%                              -12.32%  
      operating margin %
    		-Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% 0% 0% 0% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN%  NaN% -Infinity% NaN% -Infinity% -Infinity% 
      other income:
    		                                      
      dividend/investment income
    		114,000 102,000 59,000  68,000 126,000                                 
      interest and finance expense
    		-1,240,000 -1,088,000 -639,000 -548,000 -580,000 -549,000 -927,000 -964,000                               
      change in fair value of warrant liability
    		-1,000 20,000 -1,000 17,000 18,000 4,000 -4,000 219,000 -82,000 46,000 324,000 324,000                           
      change in fair value of derivative liability
    		-1,878,000 483,000     256,000 1,058,000 -1,099,000 135,000 500,000 512,000                           
      foreign exchange gain
    		-22,250 -30,000 -18,000  -6,500 46,000 74,000 -146,000    8,000 -27,000 286,000 -217,000 -177,000 500 -8,000  9,859 117 6,147  1,275 34,048 1,765  1,724 -72 -1,246         
      loss on extinguishment of debt
    		    87,000 -1,910,000 -624,000                                
      loss on disposal of fixed assets
    		-104,000 -359,000 -46,000 -11,000 -58,250 -62,000 -171,000                                
      other income
    		6,000 -162,000 48,000 94,000 -2,000 -37,000 49,000 -2,000 -10,500 35,000  -77,000 79,250 219,000 88,000 10,000  -412,000                     
      total other income
    		-3,198,000 -1,034,000 -597,000 -461,000 -890,000 -2,381,000 -1,196,000 525,000 -1,921,000 -294,000 109,000 820,000     -779,500 -476,000 -2,490,000  -115,881.25 -153,278 -165,110  -447,088.25 342,346 171,520 -2,302,219 -3,571,443 3,361,820         
      income before income taxes
    		-10,368,000 -7,630,000 -8,258,000 -8,078,000                                   
      provision for income taxes
    		                                      
      net income
    		-10,368,000 -7,630,000 -8,258,000 -8,078,000 -8,063,000 -13,333,000 -14,029,000 -13,055,000 -14,556,000 -17,258,000 -17,426,000 -15,055,000 -21,151,000 -13,798,000 -12,797,000 -11,654,000 -20,663,000 -7,962,000 -8,692,000 -6,742,884 -5,231,486 -5,769,651 -5,131,790 -6,741,804 -5,268,332 -4,395,611 -4,097,740 -6,180,821 -57,922 957,581 4,463,000 3,001,000   -9,138  -2,591 -2,947 
      yoy
    		28.59% -42.77% -41.14% -38.12% -44.61% -22.74% -19.49% -13.28% -31.18% 25.08% 36.17% 29.18% 2.36% 73.30% 47.23% 72.83% 294.97% 38.00% 69.38% 0.02% -0.70% 31.26% 25.23% 9.08% 8995.56% -559.03% -191.82% -305.96%   -48940.01%        
      qoq
    		35.88% -7.60% 2.23% 0.19% -39.53% -4.96% 7.46% -10.31% -15.66% -0.96% 15.75% -28.82% 53.29% 7.82% 9.81% -43.60% 159.52% -8.40% 28.91% 28.89% -9.33% 12.43% -23.88% 27.97% 19.85% 7.27% -33.70% 10570.94% -106.05% -78.54% 48.72%      -12.08%  
      net income margin %
    		-Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -3097.02% -4413.81% -7291.21% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% Infinity% Infinity%  NaN% -Infinity% NaN% -Infinity% -Infinity% 
      less: net loss attributable to non-controlling interest
    		-86,000 -294,000 -318,000 -387,000                                   
      net loss attributable to beyond air, inc.
    		-10,282,000 -7,336,000 -7,940,000 -7,691,000 -8,034,000 -13,032,000 -13,358,000 -12,201,000 -13,707,000 -16,220,000 -16,220,000  -20,167,000 -12,747,000 -11,968,000 -10,934,000 -5,793,500 -7,739,000                     
      other comprehensive income, net of tax
    		                                      
      foreign currency translation adjustment
    		24,000 25,000                                     
      comprehensive loss attributable to beyond air, inc.
    		-10,258,000 -7,311,000 -7,922,000 -7,564,000 -8,042,000 -13,093,000 -13,438,000 -12,098,000 -13,756,000 -16,229,000 -16,255,000 -14,070,000 -20,369,000 -12,931,000 -11,797,000 -10,762,000                       
      net basic and diluted loss per share attributable to beyond air, inc.
    		-0.57 -0.85 -1.25 -1.53 -0.05 -0.15 -0.28 -0.27 -0.36 -0.5 -0.51  -0.298 -0.43 -0.4 -0.37 -0.238 -0.29                     
      weighted-average number of shares of common stock outstanding, basic and diluted
    		 8,616,860 6,356,573                                    
      gross loss
    		  -298,000  -32,000 -215,000 -1,084,000 -332,000 -513,000 -356,000 -193,000 -244,000                           
      foreign currency translation loss
    		  18,000  -8,000 -61,000 -79,000                                
      dividend and interest income
    		   28,000    361,000           1,000  660 378 878                
      foreign exchange loss
    		   -41,000       -42,000            -6,954    -1,977            
      foreign currency translation gain
    		   127,000    103,000 -49,000 -9,000 -35,000 25,000   171,000 172,000                       
      weighted-average number of shares of common stock outstanding - basic and diluted
    		   5,014,923                                   
      estimated liability for contingent loss
    		        -152,250 -11,000 -400,000 -198,000 -62,000 -248,000   307,000  -2,330,000                    
      net loss before income taxes
    		    -10,104,000 -13,333,000 -14,029,000 -13,055,000                               
      less : net loss attributable to non-controlling interest
    		    -456,250 -300,000 -671,000 -854,000 -801,000 -1,038,000  -960,000                           
      weighted-average number of shares, outstanding, basic and diluted
    		     88,074,511 47,118,535   32,462,476 31,800,492   29,921,254 29,898,825                        
      dividend/interest income
    		      150,000                                
      weighted-average number of shares, outstanding basic and diluted
    		       45,900,821        29,888,004  26,822,302                     
      revenue
    		        470,000 391,000 239,000                            
      yoy
    		                                      
      qoq
    		        20.20% 63.60%                             
      cost of revenue
    		        -3,949,000 748,000 432,000  -802,000 68,000 179,000                        
      general and administrative
    		        -6,422,000 -9,768,000 -10,211,000  -59,838,000 8,941,000 7,990,000 8,214,000 -30,596,000 4,943,000 3,395,000 3,850,265 -17,602,431 2,471,065 2,169,011 2,494,014 -2,163,975 -2,471,714 -2,064,872 2,182,558 -11,125,787 1,817,543     8,684  2,540 2,897 
      operating expenses
    		        -12,394,500 -16,606,000 -17,342,000 -15,631,000 9,455,750 13,941,000 12,442,000 11,440,000 5,069,750 7,486,000 6,201,000  4,476,820.5 5,765,167 5,316,287  -3,618,317.25 -5,052,336 -4,914,862            
      operating income
    		        -12,593,000 -16,963,000 -17,535,000 -15,875,000 -9,517,500 -14,010,000 -12,621,000 -11,440,000 -5,069,750 -7,486,000 -6,201,000 -6,591,306 -4,294,930 -5,616,373 -4,966,680 -6,596,667 -5,256,116 -4,737,957 -4,269,260 -3,878,602 3,513,521 -2,404,239 2,413,000 1,756,000       
      dividend/interest income and gains on marketable securities
    		        359,500 388,000 641,000                            
      interest expense
    		        -497,750 -919,000 -914,000 -158,000 -35,500 -46,000 -48,000 -48,000 -94,250 -57,000 -161,000 -162,143 -120,058.5 -157,960 -159,034 -163,240               
      foreign exchange gain and loss
    		        -750 31,000                             
      benefit from income taxes
    		                                      
      less : net loss attributable to non-controlling interests
    		          -1,205,000  -650,250 -1,051,000 -830,000 -720,000 -55,750 -223,000                     
      dividend / interest income and gains on marketable securities
    		           409,000                           
      net loss attributable to beyond air, inc. stockholders
    		           -14,095,000                           
      net basic and diluted loss per share of common stock attributable to beyond air, inc.
    		           -0.45                           
      net basic loss per share attributable to beyond air, inc.
    		           -0.45                           
      net diluted loss per share attributable to beyond air, inc.
    		           -0.45                           
      weighted average number of shares, outstanding basic and diluted
    		           31,382,986                           
      weighted average number of shares, outstanding basic
    		           31,382,986                           
      weighted average number of shares, outstanding diluted
    		           31,382,986                           
      total other expense
    		            -45,000 211,000 -177,000 -215,000                       
      foreign currency translation gain and loss
    		            39,750 -184,000                         
      license revenues
    		                    181,890.5 148,794 349,607 229,161 396,862.5 314,379 645,602 627,469           
      benefit for income taxes
    		                                      
      net basic and diluted loss per share
    		                  -0.36  -0.258 -0.33 -0.3  -0.365 -0.43     0.53 0.36       
      weighted average number of shares of common stock used in computing basic and diluted net loss per share
    		                  24,165,965   17,609,328    11,398,413             
      license revenue
    		                                      
      dividend income
    		                   706    14,985 55,957 25,692 30,691 3,376 10,519 13,737         
      other
    		                       1,843               
      total other loss
    		                   -151,578    -145,137               
      net income per share
    		                   -0.31    -0.4    -0.67  0.11         
      weighted-average number of common shares outstanding – basic and diluted
    		                   21,945,235    16,529,392    9,201,855           
      realized and unrealized gain from marketable securities
    		                        -462,406 314,889 142,806            
      other loss
    		                     -1,843                 
      deemed dividend from warrant modification
    		                         -522,478             
      net loss attributed to common shareholders
    		                    -4,410,811.25 -5,769,651   -3,799,162.5 -4,918,089             
      weighted-average number of shares of common stock used in computing basic and diluted net loss per share
    		                      17,120,801    10,699,370    8,440,457 8,400,327       
      realized and unrealized loss on marketable equity securities
    		                           -2,307,319           
      other expenses
    		                                      
      net basis and diluted loss per share
    		                          -0.38            
      unrealized gain on marketable securities
    		                            3,285.5 4,365         
      total other comprehensive loss
    		                           -6,180,821           
      change in fair value of warrant liabilities
    		                             3,351,232         
      other expense
    		                            -724.25 -1,903         
      total comprehensive income
    		                            -1,621,846.5 961,946         
      net income (loss) per share – diluted
    		                            -0.193 0.11         
      weighted average number of common shares outstanding - basic
    		                             8,530,580         
      weighted average number of common shares outstanding - diluted
    		                            8,498,525 8,554,320         
      research and development expenses
    		                              648,000 1,063,000       
      general and administrative expenses
    		                              1,765,000 693,000       
      financial expense
    		                              2,050,000 1,245,000       
      net unrealized gain on available-for-sale investments
    		                              3,000 5,000       
      total comprehensive loss
    		                              4,460,000 2,996,000       
      loss before taxes on income
    		                               3,001,000       
      taxes on income
    		                                      
      net revenue
    		                                      
      interest expense - related party
    		                                  -454  -51 -50 
      net loss per common share
    		                                      
      basic and diluted
    		                                      
      weighted-average number of common shares
    		                                      
      basic and diluted
    		                                 103,200 10,320,000 10,320,000 10,320,000 10,320,000 
      see notes to the financial statements
    		                                      
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 
                                
        assets
      		                          
        current assets
      		                          
        cash and cash equivalents
      		6,740,000 6,643,000 9,699,000 4,976,000 4,665,000 4,601,000 28,447,000 4,161,000 11,378,000 7,971,000 13,179,000 31,348,000 29,158,000 25,478,000 29,829,000 72,773,000 80,242,000 83,468,000 47,699,000 38,581,386 7,141,000 41 2,941 5,918 2,994 5,533 
        marketable securities
      		4,901,000 5,018,000 996,000 1,487,000 2,252,000 6,349,000  17,213,000 23,090,000 23,292,000 25,463,000 25,644,000 16,724,000 27,641,000 32,617,000            
        restricted cash
      		5,622,000 6,187,000 163,000 163,000 231,000 232,000 230,000 229,000 230,000 231,000 5,231,000 2,740,000 10,129,000 10,085,000 10,106,000 9,989,000 9,988,000 9,239,000 1,047,000 1,046,606       
        accounts receivable
      		1,086,000 1,151,000 892,000 804,000 710,000 639,000 556,000 475,000 319,000 294,000 205,000 44,000               
        inventory
      		1,406,000 1,761,000 2,229,000 2,433,000 2,417,000 2,379,000 2,527,000 2,391,000 2,127,000 1,533,000 1,574,000 1,339,000 1,129,000 955,000 711,000 686,000           
        other current assets and prepaid expenses
      		5,012,000 4,804,000 4,607,000 5,126,000 5,743,000 5,144,000 6,275,000 6,405,000 6,792,000 6,118,000 1,481,000 1,823,000 1,850,000 1,500,000 1,581,000 1,497,000 2,393,000 1,317,000 1,550,000 1,325,064       
        total current assets
      		24,767,000 25,564,000 18,586,000 14,989,000 16,018,000 19,344,000 38,036,000 30,874,000 43,936,000 39,439,000 47,134,000 63,363,000 59,410,000 66,015,000 75,078,000 85,424,000 92,945,000 94,684,000 50,295,000 40,953,056 7,318,000 67     
        licensed right to use technology
      		1,018,000 1,069,000 1,120,000 1,171,000 1,222,000 1,274,000 1,325,000 1,376,000 1,427,000 1,478,000 1,529,000 1,581,000 1,632,000 1,683,000 1,734,000 1,785,000 1,837,000 346,000 356,000 365,158       
        right-of-use lease assets
      		1,193,000 1,464,000 1,561,000 1,654,000 1,706,000 1,775,000 1,897,000 2,021,000 2,121,000 2,229,000 2,294,000 2,401,000 2,493,000 2,426,000 2,265,000 2,354,000 2,216,000 2,299,000 1,769,000 1,815,351       
        property and equipment
      		8,249,000 8,502,000 9,392,000 10,188,000 11,013,000 11,652,000 11,648,000 12,117,000 9,364,000 8,551,000 6,824,000 5,474,000 5,003,000 3,624,000 2,757,000 2,132,000 1,995,000 1,772,000 1,424,000 897,550 80,000      
        other assets
      		158,000 175,000 306,000 112,000 103,000 100,000 105,000 112,000 113,000 213,000 224,000 226,000 212,000 211,000 205,000 209,000 207,000 209,000 211,000 137,880       
        total assets
      		35,385,000 36,774,000 30,965,000 28,114,000 30,062,000 34,144,000 53,010,000 46,500,000 56,961,000 51,911,000 58,005,000 73,044,000 68,749,000 73,959,000 82,039,000 91,904,000 99,199,000 99,311,000 54,056,000 44,168,995 7,398,000 67 2,967 5,944 3,020 5,559 
        liabilities and stockholders’ equity
      		                          
        current liabilities
      		                          
        accounts payable
      		2,417,000 2,202,000 1,915,000 1,242,000 1,950,000 2,357,000 1,490,000 3,114,000 1,948,000 3,220,000 3,292,000 1,738,000 2,016,000 1,411,000 2,006,000 1,038,000 1,129,000 1,611,000 2,241,000 2,261,777  41,706 6,341 634   
        accrued expenses and other current liabilities
      		3,372,000 2,401,000 2,055,000 2,737,000 2,045,000 2,631,000 4,470,000 7,674,000 8,402,000                  
        operating lease liabilities, current portion
      		321,000 386,000 413,000                        
        loans payable, current portion
      		401,000   233,000 609,000 60,000 258,000 536,000 800,000 130,000 275,000 495,000 775,000              
        total current liabilities
      		6,511,000 4,989,000 4,383,000 4,626,000 5,000,000 5,430,000 6,599,000 11,753,000 11,567,000 11,641,000 12,454,000 12,016,000 19,780,000 11,597,000 11,598,000 10,160,000 10,712,000 6,178,000 6,912,000 4,493,465 1,640,000 73,613     
        operating lease liabilities
      		1,023,000 1,231,000 1,300,000                        
        long-term debt
      		21,639,000 21,974,000 10,085,000 9,621,000 9,197,000  10,940,000 14,946,000 14,721,000 14,380,000 14,044,000 13,749,000 120,000 140,000 200,000 200,000  200,000 4,539,000 4,505,393       
        warrant liability
      		2,000 2,000 21,000 21,000 38,000 56,000 60,000 56,000 275,000 192,000 238,000 561,000               
        total liabilities
      		29,175,000 28,488,000 17,870,000 17,706,000 15,721,000 15,763,000 23,716,000 28,801,000 29,775,000 28,440,000 29,173,000 33,901,000 26,721,000 18,519,000 18,387,000 20,553,000 20,990,000 8,540,000 13,134,000 10,719,247 6,526,000 73,613 37,265 31,104 10,159 10,108 
        commitments and contingencies
      		                          
        stockholders’ equity
      		                          
        preferred stock, 0.0001 par value per share...
      		                          
        common stock, 0.0001 par value per share...
      		1,000 1,000 1,000  8,000 7,000 7,000 5,000 5,000 4,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 3,000 2,327       
        treasury stock
      		-25,000 -25,000 -25,000 -25,000 -25,000 -25,000 -25,000 -25,000 -25,000 -25,000 -25,000 -25,000 -25,000 -25,000 -25,000 -25,000 -25,000 -25,000 -25,000 -25,000       
        additional paid-in capital
      		325,587,000 317,314,000 314,625,000 303,898,000 299,982,000 296,000,000 293,391,000 267,960,000 264,780,000 246,792,000 235,495,000 228,949,000 217,339,000 210,097,000 204,930,000 200,448,000 196,269,000 188,652,000 136,840,000 120,677,112  5,090 4,068 4,068 4,068 4,068 
        accumulated deficit
      		-319,571,000 -309,289,000 -301,953,000 -294,013,000 -286,322,000 -278,288,000 -265,255,000 -251,898,000 -239,697,000 -225,990,000 -209,770,000 -193,550,000 -179,455,000 -159,288,000 -146,541,000 -134,573,000 -123,639,000 -103,636,000 -95,897,000 -87,204,691     -12,239 -9,649 
        accumulated other comprehensive income
      		134,000 110,000 85,000 67,000  -51,000 9,000 88,000 -15,000 34,000 43,000 78,000 53,000 159,000 438,000 268,000 96,000          
        total stockholders’ equity attributable to beyond air, inc.
      		6,126,000    13,583,000   16,130,000 25,048,000   35,455,000 37,915,000    72,704,000          
        non-controlling interest
      		84,000 175,000 362,000 481,000 758,000 738,000 1,167,000 1,570,000 2,138,000 2,657,000 3,085,000 3,688,000               
        total stockholders’ equity
      		6,210,000 8,286,000 13,095,000 10,408,000               40,921,000 33,449,748       
        total liabilities and stockholders’ equity
      		35,385,000 36,774,000 30,965,000 28,114,000 30,062,000 34,144,000 53,010,000 46,500,000 56,961,000 51,911,000 58,005,000 73,044,000 68,749,000 73,959,000 82,039,000 91,904,000 99,199,000 99,311,000 54,056,000 44,168,995       
        derivative liability
      		 292,000      256,000 1,314,000 214,000 349,000 849,000               
        total stockholders’ equity attributable to beyond air, inc
      		 8,111,000 12,733,000 9,927,000  17,644,000 28,127,000   20,814,000 25,746,000   50,946,000 58,805,000 66,120,000  84,994,000         
        other long-term liabilities
      		  2,081,000 2,019,000        4,500,000 4,500,000 4,500,000 4,500,000 8,000,000 8,000,000          
        operating lease liability, current portion
      		   414,000 396,000 381,000 381,000 429,000 418,000 408,000 391,000 382,000 376,000              
        operating lease liability
      		   1,419,000 1,486,000 1,567,000 1,690,000 1,790,000 1,898,000 2,012,000 2,087,000 2,226,000 2,321,000 349,000 348,000 290,000 281,000 239,000 178,000 187,288       
        accumulated other comprehensive loss
      		    -60,000                      
        total equity
      		    14,341,000 18,381,000 29,294,000 17,699,000 27,186,000 23,471,000 28,831,000 39,143,000 42,028,000 55,440,000 63,652,000 71,351,000 78,209,000 90,771,000         
        long-term liability, related party
      		     8,710,000                     
        long term liability, related party
      		      4,427,000                    
        grant receivable
      		           425,000 420,000 355,000 235,000 479,000 322,000 661,000         
        accrued expenses
      		         7,882,000 8,496,000 9,401,000 16,613,000 9,777,000 8,934,000 8,213,000 8,374,000 4,328,000 4,352,000 1,695,235       
        non-controlling interests
      		            4,113,000 4,494,000 4,847,000 5,230,000 5,505,000 5,777,000         
        loan payable, current portion
      		             60,000 310,000 619,000           
        long-term liabilities
      		                          
        loan payable
      		                927,000  140,000 349,165       
        long-term loan
      		                200,000          
        current assets:
      		                          
        other accounts receivables and prepaid expenses
      		                    177,000      
        non-current assets:
      		                          
        deferred private placement costs
      		                          
        total non-current assets
      		                    80,000      
        liabilities and stockholders' equity
      		                          
        current liabilities:
      		                          
        bank loan
      		                    27,000      
        trade payables
      		                    548,000      
        other accounts payable
      		                    857,000      
        loans from related parties and others
      		                    208,000      
        non-current liabilities:
      		                          
        convertible notes
      		                          
        liability related to warrants
      		                    4,886,000      
        total non-current liabilities
      		                    4,886,000      
        stockholders' equity
      		                          
        100,000,000 and 11,665,085 shares authorized at march 31, 2017 (unaudited) and december 31, 2016 respectively; 6,290,663 and 2,207,449 shares issued and outstanding shares at march 31, 2017 (unaudited) and december 31, 2016, respectively
      		                    1,000      
        10,000,000 shares authorized at march 31, 2017 (unaudited) and december 31, 2016; 0 issued and outstanding shares at march 31, 2017 (unaudited) and december 31, 2016
      		                          
        treasury shares
      		                    -25,000      
        additional paid- in capital
      		                    20,752,000      
        deficit accumulated
      		                    -19,856,000      
        total shareholders' equity
      		                    872,000      
        total liabilities and stockholders' equity
      		                    7,398,000 67 2,967 5,944 3,020 5,559 
        other current assets
      		                     26 26 26 26 26 
        other current liabilities
      		                     28,994     
        note payable - related party
      		                     2,600  10,000 10,000 10,000 
        accrued interest - related party
      		                     313     
        preferred stock, 0.0001 par value...
      		                          
        common stock, 0.0001 par value...
      		                     10  1,032 1,032 1,032 
        retained deficit
      		                     -78,646 -39,398 -30,260   
        total stockholders' equity
      		                     -73,546     
        accrued liabilities
      		                      924 470   
        note payable – related party
      		                      10,000    
        convertible notes payable
      		                      20,000 20,000   
        authorized, none issued and outstanding
      		                          
        authorized, 10,320,000 issued and outstanding
      		                      1,032    
        other liabilities
      		                        159 108 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2017-09-30 2017-06-30 2017-03-31 
                                           
          cash flows from operating activities:
        		                                   
          net loss
        		-10,368,000 -7,630,000 -8,258,000 -8,078,000 -8,063,000 -13,333,000 -14,028,000 -13,055,000 -14,556,000 -17,258,000 -17,426,000 -15,055,000 -21,151,000 -13,798,000 -12,798,000 -11,654,000 -20,663,000 -7,962,000 -8,692,116 -6,742,884 -5,231,486 -5,769,651 -5,131,790 -6,741,804 -5,268,332 -4,395,611 -4,097,740 -6,180,821  963,472   -16,312,000 -9,163,000 -6,283,000 
          adjustments to reconcile net loss to net cash from operating activities:
        		                                   
          depreciation
        		778,000 746,000 769,000 754,000                           14,000 14,000 21,000 16,000 6,000 
          stock-based compensation
        		427,000 1,503,000 1,775,000 1,577,000 158,000 2,480,000 3,129,000 3,379,000 2,327,000 6,435,000 6,460,000 6,115,000 4,354,000 5,866,000 4,714,000 4,624,000 3,344,000 2,116,000 1,155,089 1,215,911 838,787 1,060,763 1,179,714 1,815,654 1,008,141 733,474 894,497 941,537 705,422 771,899      
          amortization of debt discount and accretion of debt issuance costs
        		206,000 212,000 79,000 54,000     371,000 366,000        461,000    33,558              
          amortization of licensed right to use technology
        		51,000 51,000 51,000 51,000 51,000 52,000 51,000 51,000 51,000 52,000 50,000 52,000 51,000 52,000 33,000 69,000 9,000 10,000 9,472 9,528  11,371 9,519 9,519            
          amortization of operating lease assets
        		86,000 95,000 96,000 121,000 98,000 63,000 112,000 94,000 96,000 101,000 85,000 90,000 94,000 99,000    69,000     19,914 16,513            
          change in fair value of warrant liability
        		1,000 -20,000 1,000 -17,000 -18,000 -5,000 5,000 -219,000 82,000 -46,000 -323,000 -324,000                        
          change in fair value of derivative liability
        		1,878,000    0 0 -256,000 -1,058,000 1,099,000 -135,000 -500,000 -512,000                        
          unrealized loss on marketable securities
        		   -9,000                                
          provision for inventory losses
        		186,000 247,000 135,000 104,000 -164,000 8,000       0 0                      
          provision for bad debt
        		                                   
          foreign currency adjustments
        		27,000 -8,000 -10,000 -128,000      -14,000 9,000 -8,000  -250,000 217,000 177,000  -2,000    -6,147              
          loss on extinguishment of debt
        		    -87,000 1,910,000                              
          impairment of fixed assets
        		                                   
          loss on disposal of fixed assets
        		15,000 359,000 46,000 11,000                                
          paid in kind interest
        		464,000 461,000 448,000 389,000                                
          changes in:
        		                                   
          inventory
        		194,000 424,000 304,000 188,000 126,000 140,000 -394,000 -338,000 -594,000 101,000 -296,000 -209,000 -174,000 -244,000 -74,000 -289,000                    
          accounts receivable
        		-26,000 -260,000 -88,000 -94,000 -70,000 -83,000 -81,000 -156,000 -25,000 -89,000 -161,000 -44,000                        
          other current assets and prepaid expenses
        		-192,000 -66,000 324,000 617,000 -601,000 1,133,000 125,000 391,000 166,000 -2,116,000 293,000 74,000 427,000 70,000 -88,000 509,000 -562,000 -234,000 -225,032 205,032 -1,203,733 13,549 729,446 -57,432 -720,024 -15,745 131,116 243,258 -702,699 38,540      
          accounts payable
        		392,000 -90,000 673,000 -708,000 85,000 831,000 -1,008,000 491,000 -807,000 -937,000 1,583,000 -306,000 1,176,000 -1,202,000 1,028,000 -164,000 -613,000 -623,000 -37,648 946,648 64,175 -595,781 -100,248 -335,893 242,298 -90,392 551,321 388,330 330,403 -27,770      
          accrued expenses
        		770,000 348,000 -682,000 691,000 -546,000 -1,880,000 -3,084,000 -848,000 527,000 -632,000 -5,377,000 -7,228,000 7,047,000 852,000 -2,984,000 -124,000  -50,000 2,660,701 -109,701 370,849 86,581 262,801 -12,830 -577,536 -393,179 553,699 -53,089 1,245,043 -59,286      
          operating lease liabilities
        		-108,000 -95,000 -121,000 -49,000 -66,000 -73,000 -149,000 -97,000   -110,000 -84,000                        
          net cash from operating activities
        		-4,946,000 -4,219,000 -4,453,000 -4,526,000 -6,957,000 -7,733,000 -13,348,000 -10,180,000 -10,725,000 -13,817,000 -14,319,000 -17,153,000 -8,440,000 -8,510,000 -9,219,000 -6,840,000 -7,900,000 -6,336,000 -4,979,822 -3,918,178 -5,569,241 -5,264,343 -3,320,327 -5,485,465    -2,909,911  -1,640,315 -1,804,000 -2,304,000 -5,313,000 -3,913,000 -2,212,000 
          capital expenditures
        		-547,000 -34,000 -246,000 -198,000 -1,498,000 -537,000 -1,175,000 -2,673,000 -1,931,000 -1,337,000 -1,682,000 -795,000 -2,022,000 -634,000 -963,000 -258,000 -342,000 -419,000 -591,945 -27,055 -19,950 -139,319 -487,611 -243,527    -3,112  -18,259 0 0 -108,000 -71,000 -25,000 
          free cash flows
        		-5,493,000 -4,253,000 -4,699,000 -4,724,000 -8,455,000 -8,270,000 -14,523,000 -12,853,000 -12,656,000 -15,154,000 -16,001,000 -17,948,000 -10,462,000 -9,144,000 -10,182,000 -7,098,000 -8,242,000 -6,755,000 -5,571,767 -3,945,233 -5,589,191 -5,403,662 -3,807,938 -5,728,992    -2,913,023  -1,658,574 -1,804,000 -2,304,000 -5,421,000 -3,984,000 -2,237,000 
          cash flows from investing activities:
        		                                   
          purchase of marketable securities
        		-41,000 -4,009,000 0 -3,000 0 -12,397,000 -3,907,000 -14,574,000 -54,300,000 -19,257,000 -45,469,000 -9,744,000 -2,879,000 -160,000                      
          proceeds from sale of marketable securities
        		141,000 0 486,000 777,000 4,079,000 5,996,000 21,220,000 20,361,000 54,564,000 21,447,000 45,383,000 886,000 13,757,000                       
          security deposits made on operating leases
        		            5,000 -6,000 8,000 -6,000                    
          purchase of property and equipment
        		-547,000 -34,000 -246,000 -198,000 -1,498,000 -537,000 -1,175,000 -2,673,000 -1,931,000 -1,337,000 -1,682,000 -795,000 -2,022,000 -634,000 -963,000 -258,000 -342,000 -419,000 -591,945 -27,055 -19,950 -139,319 -487,611 -243,527 -15,383 -10,512 -14,624 -3,112 -4,216 -18,259   -108,000 -71,000 -25,000 
          net cash from investing activities
        		-447,000 -4,043,000 240,000 576,000     -1,667,000 853,000 -1,768,000 -9,653,000 8,860,000 4,388,000 -33,571,000 -264,000 -339,000 -419,000 -664,945 -27,055 -19,950 -139,319 -487,611 -243,527    -6,775,002 -7,272,162 1,757,523 1,754,000 1,967,000 -2,403,000 -366,000 -320,000 
          cash flows from financing activities:
        		                                   
          proceeds from issuance of common stock through at the market offerings
        		0 0 5,694,000 2,441,000 1,509,000 0   1,403,000 5,472,000 687,000 5,814,000 3,491,000 0                      
          proceeds from the sale of common stock of neuronos
        		0 200,000                                  
          proceeds from issuance of common stock and pre-funded warrants through securities purchase
        		                                   
          proceeds from issuance of common stock through exercise of warrants
        		0 1,000                                  
          proceeds from issuance of common stock warrants
        		                                   
          proceeds from long term loan
        		   2,000,000 0                               
          debt issuance costs
        		0                                   
          payment of loan
        		    626,000 -12,952,000 -5,462,000 -264,000 -100,000 -235,000 -220,000 -280,000 -82,000 -310,000 -81,000 -536,000 -23,000 -182,000 -245,651 -207,349 -68,736 -84,280 -125,299 -125,779 -40,202 -88,582 -58,656 -116,366        
          net cash from financing activities
        		4,901,000 11,205,000 8,918,000 4,066,000 4,500,000 -9,214,000       3,409,000 -310,000 133,000 -536,000 5,667,000 50,715,000 14,762,482 8,305,518 18,202,889 5,704,449 1,715,943 4,709,098    8,980,796 1,044,320 46,170   9,461,000 9,461,000 9,666,000 
          effect of exchange rate changes on cash and cash equivalents
        		24,000 25,000 18,000 127,000 -61,000 39,000 -134,000 111,000 -95,000 37,000 -59,000 40,000 -106,000 61,000 -170,000 172,000                    
          increase in cash, cash equivalents and restricted cash
        		-468,000 2,968,000 4,723,000 243,000  -23,845,000       3,723,000 -4,371,000 -42,828,000 -7,468,000 -2,477,000   4,360,285     22,688,585 421,903      -337,000    
          cash, cash equivalents and restricted cash at beginning of year
        		                                   
          cash, cash equivalents and restricted cash at end of year
        		                                   
          supplemental disclosure of non-cash investing and financing activities:
        		                                   
          debt discount
        		0    2,989,000 -593,000 232,000 621,000 0 0 0 4,541,000                        
          derivative liability
        		0     0   0 0 0 -1,361,000                        
          short term finance liability
        		                                   
          fixed assets recorded in accounts payable and accrued expenses
        		                                   
          right-of-use assets acquired under operating leases
        		                                   
          debt principal balance converted to equity
        		                                   
          interest paid
        		116,000 112,000 99,000 96,000 85,000 2,000 554,000 556,000 564,000 826,000 80,000 289,000 11,000 9,000 6,000 10,000 6,000 155,000 42,968 136,032 167,711 259,926 58,555 22,298 19,280 750 1,406 1,676        
          income taxes paid
        		             23,000   0                   
          cash flows from operating activities
        		                                   
          adjustments to reconcile net loss to net cash from operating activities
        		                                   
          unrealized gain in marketable securities
        		 -13,000    51,000    -6,000                          
          cash flows from investing activities
        		                                   
          issue of/return of security deposits
        		     0                              
          cash flows from financing activities
        		                                   
          issuance of common stock warrants
        		 0                                  
          issuance of common stock and pre-funded warrants through securities purchase agreement ii
        		     0                              
          proceeds from long-term loan
        		 12,000,000                                  
          payment of loans
        		 0 -234,000 -375,000                                
          cash, cash equivalents and restricted cash at beginning of period
        		 0 0 4,896,000  0 0 11,608,000  -2,519,000 0 39,287,000  0 0 90,230,000 0 0 293 35,267,707 0 0 0 25,465,111 0 0 0 1,357,137 0       
          cash, cash equivalents and restricted cash at end of period
        		 2,968,000 4,723,000 5,139,000  -23,844,000 24,287,000 4,390,000  -10,208,000 -15,678,000 34,088,000  -4,371,000 -42,828,000 82,762,000 -2,477,000 43,961,000 9,118,008 39,627,992 12,613,698 300,787 -2,091,995 24,445,217 22,688,585 421,903 1,701,603 653,020 861,525       
          supplemental disclosure of non-cash investing and financing activities
        		                                   
          end of term loan liability
        		     -134,000 300,000 -438,000 0 0 0 -613,000                        
          warrant liability
        		     -5,000   0 0 0 -885,000                        
          right-of-use assets
        		     0        192,000 31,000 243,000      0 0 236,700  0 0 258,605        
          operating lease liability
        		     0       143,000 192,000 31,000 243,000 91,000    1,540,492 0 0 236,700 304,388 -306,388 0 266,570        
          fixed assets included in accounts payable
        		                                   
          supplemental disclosure of cash flow items:
        		                                   
          loss on termination of right of use asset
        		                                   
          cash receivable as part of securities purchase agreement ii
        		                                   
          fixed assets included in accounts payable and accrued expenses
        		                                   
          grant receivable
        		        0 0 425,000 -5,000 -65,000 -120,000 244,000 -157,000 -130,000 -192,000 0 425,000                
          proceeds from issuance of common stock and pre-funded warrants through securities purchase agreement ii
        		                                   
          proceeds from issuance of common stock in connection with a purchase agreement
        		                                   
          proceeds from issuance of common stock through exercise of options
        		                                   
          decrease in cash, cash equivalents and restricted cash
        		       -7,218,000 3,405,000 -7,689,000 -15,677,000 -5,199,000            -1,019,894    -704,117  163,378      
          depreciation and amortization
        		     741,000 783,000 685,000  503,000 373,000 309,000  204,000 114,000 121,000 121,000 70,000 64,653 58,347 85,943 51,428 39,958 33,650    90,951 18,565       
          amortization of debt discount
        		     119,000 369,000 409,000    57,000        33,192    33,192            
          loss on termination of right-of use-asset
        		                                   
          write-off of assets no longer used
        		     163,000                              
          net cash from and (used in) investing activities
        		     -6,937,000 16,147,000 3,114,000                            
          proceeds from loan
        		        0 1,000 0 15,817,000                        
          un-realized gain in marketable securities
        		       90,000    -75,000                        
          proceeds from issuance of common stock through exercise of stock options
        		         0 0 217,000                        
          net cash (used in) and provided by financing activities
        		       -264,000                            
          fixed assets recorded in accounts payable and accrued assets
        		       749,000                            
          adjustments to reconcile net loss used in provided by operating activities
        		                                   
          disposal of clinical and medical equipment
        		            0                       
          right-of-use lease assets
        		                                   
          net cash from and (used in) financing activities
        		         5,238,000 469,000 21,567,000                        
          unrealized gain on marketable securities
        		            26,000                 5,142      
          long-term accrued liabilities
        		                                   
          proceeds from the sale of common stock of beyond cancer
        		                                   
          proceeds from the net recovery of short-swing profits from related parties
        		                                   
          accelerated amortization of debt discount costs on retirement of debt
        		                                   
          increase in licensed right to use technology from nitricgen agreement
        		                                   
          nitricgen accrued liability due to fda approval
        		                                   
          proceeds from the sale of common stock – beyond cancer
        		                                   
          operating lease expense
        		               49,000    50,608                
          gain on cancellation of operating lease
        		                    0 0 0 -1,843            
          foreign currency adjustment
        		                   -9,859                
          amortization of debt issuance cost and deferred financing fees
        		                                   
          current accrued expenses
        		                                   
          deferred revenue
        		                    -145,628 -148,794 -349,607 -229,161 197,346 -314,379 -645,602 -627,469        
          security deposits made on rental properties
        		                4,000 0                  
          issuance of common stock in connection with a purchase agreement
        		                                   
          issuance of common stock in connection with at the market offering
        		                                   
          proceeds from the exercise of warrants
        		                                   
          proceeds from the exercise of stock options
        		                        92,700 8,168 25,925 83,857        
          net proceeds from the sale of common stock of beyond cancer
        		                                   
          supplemental disclosure of non-cash financing and investing activities:
        		                                   
          accelerated accretion of debt discount
        		                                   
          increase licensed right to use technology from nitricgen agreement
        		                                   
          proceeds from the sale of common stock - beyond cancer
        		                                   
          disposition of right-of-use asset
        		                     0 -60 -17,426            
          disposition of operating lease liability
        		                     0 0 19,329            
          stock issued to investor relations firm
        		                     0 0 242,100            
          lease payments
        		                      -19,271 -15,030   -4,581 -19,927        
          issuance of common stock in connection with a purchase agreement with lincoln park, at the market offerings, private placement, net, exercise of warrants and stock options
        		                     5,788,729 1,841,242 4,834,877            
          (decrease) increase in cash, cash equivalents and restricted cash
        		                                   
          adjustments to reconcile net loss to net cash used in operating activities
        		                                   
          issuance of common stock in connection with a purchase agreement with lincoln park, at- the market equity offering, private placement, net, exercise of warrants and stock options
        		                   8,512,867                
          supplemental disclosure of non-investing activities
        		                                   
          realized and unrealized loss on marketable securities sold
        		                                   
          investment in available for sale marketable equitable securities
        		                                   
          proceeds from redemption of marketable securities
        		                        16,823,536 16,214,722 -938,080 9,687,121 4,754,828 1,914,782 1,816,000 2,000,000    
          issuance of common stock in connection with a purchase agreement with lincoln park, at the market equity offering, private placement, net, exercise of warrants and stock options
        		                                   
          proceeds from facility agreement
        		                                   
          payment of debt issuance costs
        		                                   
          deemed dividend as a result of a warrant modification
        		                        0           
          fair market value of warrants allocated to debt discount and stockholders’ equity
        		                                   
          operating leases
        		                                   
          realized and unrealized loss on marketable equity securities
        		                           2,307,319        
          investment in marketable equity securities
        		                                   
          investment in marketable securities
        		                         -21,113,978 4,602,305 -16,459,011   -28,000 -33,000 -2,000,000   
          payment of operating lease liability
        		                                   
          unrealized and realized loss on marketable securities to available for sale marketable securities
        		                                   
          change of management’s assessment of prior year research and development to licensing right to use technology
        		                                   
          adoption of asu 2016-01
        		                                   
          investment in available for sale marketable securities
        		                                   
          cash flows provided by from financing activities
        		                                   
          issuance of common stock in an underwritten offering and private placement, net of offering costs
        		                        0           
          issuance of common stock in private placement, net of offering costs
        		                        0           
          issuance of common stock related to at the market offerings, net of offering costs
        		                        5,763,018 0          
          issuance of common stock, net of offering cost
        		                            772,015 46,170      
          proceeds from credit facility loan
        		                                   
          right of use assets
        		                                   
          fair market value of options issued to nitricgen for the licensing right to use technology
        		                                   
          depreciation and amortization of property and equipment
        		                         23,190          
          amortization of intangible asset
        		                         9,519          
          amortization right- of-use lease assets
        		                         16,064          
          realized and unrealized loss from marketable securities
        		                         -314,889          
          net cash used in operating activities
        		                         -4,757,258          
          licensed right to use technology
        		                                   
          net cash (used in) provided by investing activities
        		                         -4,909,768          
          net cash provided by financing activities
        		                                   
          fair market value of option to nitricgen for the licensed right to use technology
        		                                   
          issuance of common stock in private placement, net of offering cost
        		                          0 7,839,495        
          net cash provided by (used in) financing activities
        		                                   
          issuance of common stock related to at the market offerings
        		                           1,173,810        
          net income
        		                               -3,001,000    
          adjustments to reconcile net income to net cash from operating activities
        		                                   
          unrealized loss on marketable securities to available for sale marketable securities
        		                                   
          change in fair value of warrant liabilities
        		                                   
          amortization of beneficial conversion feature and debt discount related to convertible notes upon merger
        		                                   
          issuance cost related to warrants liability
        		                                   
          imputed interest on convertible notes and others
        		                                   
          issuance of common stock to finder upon the conversion of convertible notes
        		                                18,000 18,000 18,000 
          net cash from (used) in operating activities
        		                                   
          purchase price paid for the merger
        		                                   
          cash flows (used in) from financing activities
        		                                   
          proceeds from the issuance of units consisting of common stock and warrants, net of offering cost
        		                                   
          purchase of treasury stock
        		                                   
          maturity of loan and interest from related parties and others
        		                                -418,000 -418,000  
          proceeds from issuance of convertible notes, net of issuance cost
        		                                   
          proceeds from loan from related parties and others
        		                                57,000 57,000 57,000 
          cash received for the exercise of stock options
        		                                   
          increase (decrease) in cash, cash equivalents and restricted cash
        		                                   
          supplemental disclosure of non-cash investing activities:
        		                                   
          conversion of convertible notes to common stock
        		                                   
          issuance cost related to warrants
        		                                   
          fair market value of stock to be issued to vendor
        		                                   
          imputed interest on loans due to former owners
        		                                   
          licensing right to use technology
        		                                   
          payment of loan and interest to former owners
        		                                   
          payment of line of credit
        		                                   
          exercise of options
        		                                   
          imputed interest on loans from related parties and others
        		                              0 1,000    
          change in:
        		                                   
          payment of loans and interest from related parties and others
        		                                   
          payment of bank loan
        		                                   
          cash, cash equivalents and restricted cash at beginning of the period
        		                              0 739,000    
          cash, cash equivalents and restricted cash at end of the period
        		                              -69,000 402,000    
          stock-based compensation related to options, warrants, rss and rsus
        		                               80,000    
          revaluation of warrants to purchase common stock
        		                               1,277,000 3,625,000 -1,459,000 -1,308,000 
          other accounts receivables and prepaid expenses
        		                               -57,000 -36,000 -110,000  
          trade payables
        		                               -87,000 -126,000 -88,000 20,000 
          other accounts payable
        		                               -531,000 -633,000 -790,000 -410,000 
          repayment of bank loan
        		                                -42,000 -42,000 -14,000 
          capital loss in respect to property and equipment
        		                                   
          stock-based compensation warrants, rss and rsus
        		                                   
          amortization of beneficial conversion feature and debt issuance costs related to convertible notes
        		                                   
          issuance cost related to liability warrants
        		                                   
          adjustment of liability warrants
        		                                   
          imputed interest on convertible notes, loans from related parties and others
        		                                   
          waiver of salary by the company's officer
        		                                   
          deferred ipo costs that was aborted
        		                                   
          increase in restricted cash
        		                                   
          selling of property and equipment
        		                                   
          purchase price that has been paid upon the reverse merger
        		                                -295,000 -295,000 -295,000 
          proceeds from issuance of units consisting of common stock and warrants, net of issuance costs
        		                                9,889,000   
          proceeds from bank loan
        		                                   
          treasury shares
        		                                -25,000 -25,000 -25,000 
          proceeds from issuance of convertible note
        		                                   
          deferred private placement costs that were paid
        		                                   
          increase in cash and cash equivalents
        		                                   
          cash and cash equivalents at the beginning of the year
        		                                   
          cash and cash equivalents at the end of the year
        		                                   
          supplemental disclosure of non‑cash financing activities:
        		                                   
          conversion of convertible notes into common stock
        		                                3,955,000 3,955,000 3,955,000 
          capitalization of deferred private placement costs
        		                                   
          stock-based compensation, warrants, rss and rsus
        		                                4,163,000 3,698,000  
          amortization of beneficial conversion feature and debt issuance costs in the convertible notes
        		                                1,046,000 1,046,000 1,046,000 
          issuance cost related to warrants to investors and placement agent
        		                                457,000 457,000 457,000 
          issuance of additional warrants granted to investors
        		                                2,434,000 2,434,000 2,434,000 
          imputed interest on convertible notes, loans from related parties and bank loan
        		                                30,000 28,000 30,000 
          deferred costs of ipo that was aborted
        		                                   
          selling or property and equipment
        		                                   
          change in cash and cash equivalents
        		                                1,745,000 5,182,000 7,134,000 
          cash and cash equivalents at the beginning of the period
        		                                7,000 7,000 7,000 
          cash and cash equivalents at the end of the period
        		                                1,752,000 5,189,000 7,141,000 
          proceeds from issuance of units consist of common stock and warrants, net of issuance costs
        		                                 9,889,000 9,889,000 
          stock-based compensation, warrants, rs and rsu's
        		                                  1,877,000 
          receivables and prepaid expenses
        		                                  -99,000 
          maturity of loan from related parties and others
        		                                  -241,000